Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Comparison of the efficacy and safety of ciclesonide 160 μg once daily vs. budesonide 400 μg once daily in children with asthma
Pediatric Allergy and Immunology, Volume 18, No. 5, Year 2007
Notification
URL copied to clipboard!
Description
Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 μg (ex-actuator; nominal dose 200 μg) vs. budesonide 400 μg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 μg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus™ spacer) or budesonide 400 μg once daily (via Turbohaler®) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 μg once daily and budesonide 400 μg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk. © 2007 The Authors.
Authors & Co-Authors
von Berg, Andrea
Unknown Affiliation
Engelstätter, Renate
Norway
Nycomed
Minic, Predrag
Serbia, Belgrade
Institute of Occupational Health
Sréckovic, Miodrag
Serbia, Belgrade
Pediatric Hospital for Lung Diseases
Garcia-Garcia, Maria L.
Spain, Leganes
Hospital Universitario Severo Ochoa
Latoś, Tadeusz
Poland, Karpacz
Centrum Pulmonologii I Alergologii w Karpaczu S.a.
Vermeulen, Jan H.
South Africa, Parow
Panorama Medi-clinic
Leichtl, S.
Norway
Nycomed
Hellbardt, Stefan
Norway
Nycomed
Bethke, T. D.
Norway
Nycomed
Statistics
Citations: 56
Authors: 10
Affiliations: 6
Identifiers
Doi:
10.1111/j.1399-3038.2007.00538.x
ISSN:
09056157
e-ISSN:
13993038
Research Areas
Disability
Maternal And Child Health